An interventional study of Silk surgical mesh in Breast Reconstruction, sponsored by Sofregen Medical, Inc.. Completed at 1 site in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-09.
Sponsored by Sofregen Medical, Inc. · Not applicable, Interventional, and Treatment
Prospective, single center, postmarket clinical study to obtain clinical experience with the use of SERI® Surgical Scaffold for soft tissue support and repair in breast reconstruction.
Sofregen Medical, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for enrollment, the subject must:
1. Subject had radiation therapy (XRT) prior to direct-to-implant (DTI) reconstruction, but will not have XRT following reconstruction;
2. Subject did not have XRT prior to DTI reconstruction and will not have XRT following reconstruction;
3. Subject did not have XRT prior to DTI reconstruction, but will have XRT following reconstruction.
Exclusion Criteria:
To be eligible for enrollment, the subject must not:
Device: Silk surgical mesh
Device: Silk surgical mesh
Device: Silk surgical mesh
A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
Incidence of Implant Loss
Implant Loss will be defined as situations in which the breast implant is removed and not immediately replaced.
Time frame: 24 months postoperatively
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sofregen Medical, Inc.